← Back to Screener
Redhill Biopharma Ltd. (RDHL)
Price$0.78
Favorite Metrics
Price vs S&P 500 (26W)-59.32%
Price vs S&P 500 (4W)-9.57%
Market Capitalization$4.14M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)4.90x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-54.57%
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-23.71%
Gross Margin (TTM)60.41%
Net Profit Margin (TTM)-102.30%
EPS (TTM)$-0.00
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-0.00
Revenue Growth (5Y)5.04%
EPS (Annual)$-0.00
ROI (Annual)737.69%
Gross Margin (Annual)60.31%
Net Profit Margin (5Y Avg)-16.97%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)58.59%
ROA (Last FY)-45.82%
Revenue Growth TTM (YoY)33.18%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-127.32%
Operating Margin (TTM)-156.67%
Cash Flow / Share (Annual)$-0.00
P/B Ratio67.87x
P/B Ratio (Quarterly)189.79x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.12x
Net Interest Coverage (TTM)4.20x
ROA (TTM)-68.10%
EV / EBITDA (TTM)0.30x
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)0.54x
Quick Ratio (Quarterly)0.38x
3-Month Avg Trading Volume0.34M
52-Week Price Return-64.17%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.01
P/S Ratio (Annual)0.51x
Asset Turnover (Annual)0.45x
52-Week High$3.31
Operating Margin (5Y Avg)12.82%
EPS Excl Extra (Annual)$-0.00
CapEx CAGR (5Y)-46.22%
Tangible BV CAGR (5Y)13.88%
26-Week Price Return-55.33%
Quick Ratio (Annual)0.32x
13-Week Price Return-35.98%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)0.56x
Enterprise Value$1.488
Revenue / Share Growth (5Y)-49.45%
Asset Turnover (TTM)0.67x
Book Value / Share Growth (5Y)-73.06%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.79x
Pretax Margin (Annual)-102.80%
Cash / Share (Annual)$0.00
3-Month Return Std Dev53.36%
Gross Margin (5Y Avg)50.01%
Net Income / Employee (TTM)$-0
ROE (Last FY)1155.92%
Net Interest Coverage (Annual)-1.38x
EPS Basic Excl Extra (Annual)$-0.00
Receivables Turnover (TTM)3.83x
EV / Free Cash Flow (TTM)-0.02x
Total Debt / Equity (Quarterly)9.15x
EPS Incl Extra (TTM)$-0.00
Receivables Turnover (Annual)3.14x
ROI (TTM)1078.89%
P/S Ratio (TTM)0.34x
Pretax Margin (5Y Avg)-16.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.01
Price vs S&P 500 (52W)-94.00%
Year-to-Date Return-21.07%
5-Day Price Return-2.18%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-16.67%
Net Profit Margin (Annual)-102.80%
Month-to-Date Return9.10%
Cash Flow / Share (TTM)$31.18
EBITD / Share (Annual)$-0.00
Operating Margin (Annual)-181.69%
LT Debt / Equity (Annual)9.39x
ROI (5Y Avg)83.78%
LT Debt / Equity (Quarterly)9.39x
EPS Basic Excl Extra (TTM)$-0.00
P/TBV (Quarterly)5.75x
P/B Ratio (Annual)13.88x
Inventory Turnover (TTM)1.38x
Pretax Margin (TTM)-102.30%
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)-36.67%
Beta5.01x
Revenue / Share (TTM)$0.00
ROE (TTM)1955.68%
52-Week Low$0.71
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RDHLRedhill Biopharma Ltd. | 0.34x | 33.18% | 60.41% | — | $0.78 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Redhill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases, with commercialized products Talicia and Aemcolo available in the U.S. market. The company maintains a clinical-stage pipeline of five therapeutic candidates, including Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, primarily in clinical development.